



Universiteit
Leiden
The Netherlands

Survival outcomes from a cumulative analysis of worldwide observational studies on sequential use of new agents in metastatic castration-resistant prostate cancer (vol 18, pg 69, 2020)

Caffo, O.; Wissing, M.; Bianchini, D.; Bergman, A.; Thomsen, F.B.; Schmid, S.; ... ; CASTOR Study Investigators

Citation

Caffo, O., Wissing, M., Bianchini, D., Bergman, A., Thomsen, F. B., Schmid, S., ... Oudard, S. (2020). Survival outcomes from a cumulative analysis of worldwide observational studies on sequential use of new agents in metastatic castration-resistant prostate cancer (vol 18, pg 69, 2020). *Clinical Genitourinary Cancer*, 18(4), E416-E417.
doi:10.1016/j.clgc.2020.03.014

Version: Publisher's Version
License: [Creative Commons CC BY 4.0 license](#)
Downloaded from: <https://hdl.handle.net/1887/3184655>

Note: To cite this publication please use the final published version (if applicable).

Corrigendum

Corrigendum to “Survival Outcomes From a Cumulative Analysis of Worldwide Observational Studies on Sequential Use of New Agents in Metastatic Castration-Resistant Prostate Cancer” [Clinical Genitourinary Cancer. 2020 Feb;18(1):69-76.e4]

Orazio Caffo,¹ Michel Wissing,² Diletta Bianchini,³ Andries Bergman,⁴ Frederik B. Thomsen,⁵ Sebastian Schmid,⁶ Evan Y. Yu,⁷ Evangelos Bournakis,⁸ Avishay Sella,⁹ Vittorina Zagonel,¹⁰ Ugo De Giorgi,¹¹ Marcello Tucci,¹² Hans Gelderblom,² Luca Galli,¹³ Giovanni Pappagallo,¹⁴ Emilio Bria,¹⁵ Isabella Sperduti,¹⁶ Stephane Oudard,¹⁷ on behalf of the CASTOR study investigators

¹Medical Oncology Department, Santa Chiara Hospital, Trento, Italy

²Medical Oncology Department, University Medical Centre, Leiden, the Netherlands

³Division of Clinical Studies, Prostate Cancer Targeted Therapies Group, Royal Marsden NHS Foundation Trust, Sutton, United Kingdom

⁴Division of Internal Medicine (MOD) and Oncogenomics, Netherlands Cancer Institute, Amsterdam, the Netherlands

⁵Copenhagen Prostate Cancer Center, Rigshospitalet, Copenhagen, Denmark

⁶Klinik und Poliklinik für Urologie, Klinikum rechts der Isar der Technischen Universität München, München, Germany

⁷Department of Medicine, University of Washington School of Medicine, Seattle, WA

⁸Oncology Department, ARETAEIO University Hospital of Athens, IASO General Clinic of Athens, Athens, Greece

⁹Department of Oncology, Yitzhak Shamir Medical Center, Assaf Harofe Campus Harofeh Medical Center, Sackler School of Medicine, Tel-Aviv, Israel

¹⁰Medical Oncology Department, Istituto Oncologico Veneto, Padua, Italy

¹¹Medical Oncology Department, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola, Italy

¹²Medical Oncology Department, Azienda Ospedaliera Universitaria S. Luigi Gonzaga, Orbassano, Italy

¹³Medical Oncology Department, Azienda Ospedaliera Universitaria, Pisa, Italy

¹⁴Epidemiology & Clinical Trials Office, General Hospital, Mirano, Italy

¹⁵Oncology Unit, Università Cattolica del Sacro Cuore, Fondazione Policlinico “A. Gemelli”, Rome, Italy

¹⁶Biostatistical Unit, Regina Elena National Cancer Institute, Rome, Italy

¹⁷Service de cancérologie médicale, Hôpital Européen Georges Pompidou, René Descartes University, Paris, France

The authors regret that the affiliation information for Vittorina Zagonel, Ugo De Giorgi, and Isabella Sperduti was incorrect in their published article. The correct details are given below.

Orazio Caffo,¹ Michel Wissing,² Diletta Bianchini,³ Andries Bergman,⁴ Frederik B. Thomsen,⁵ Sebastian Schmid,⁶ Evan Y. Yu,⁷ Evangelos Bournakis,⁸ Avishay Sella,⁹ Vittorina Zagonel,¹⁰ Ugo De Giorgi,¹¹ Marcello Tucci,¹² Hans Gelderblom,² Luca Galli,¹³ Giovanni Pappagallo,¹⁴ Emilio Bria,¹⁵ Isabella Sperduti,¹⁶ Stephane Oudard,¹⁷ on behalf of the CASTOR study investigators

¹Medical Oncology Department, Santa Chiara Hospital, Trento, Italy

²Medical Oncology Department, University Medical Centre, Leiden, the Netherlands

³Division of Clinical Studies, Prostate Cancer Targeted Therapies Group, Royal Marsden NHS Foundation Trust, Sutton, United Kingdom

⁴Division of Internal Medicine (MOD) and Oncogenomics, Netherlands Cancer Institute, Amsterdam, the Netherlands

⁵Copenhagen Prostate Cancer Center, Rigshospitalet, Copenhagen, Denmark

⁶Klinik und Poliklinik für Urologie, Klinikum rechts der Isar der Technischen Universität München, München, Germany

⁷Department of Medicine, University of Washington School of Medicine, Seattle, WA

⁸Oncology Department, ARETAEIO University Hospital of Athens, IASO General Clinic of Athens, Athens, Greece

⁹Department of Oncology, Yitzhak Shamir Medical Center, Assaf Harofe Campus Harofeh Medical Center, Sackler School of Medicine, Tel-Aviv, Israel

¹⁰Medical Oncology Department, Veneto Institute of Oncology IOV – IRCCS, Padua, Italy

¹¹Medical Oncology Department, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy

¹²Medical Oncology Department, Azienda Ospedaliera Universitaria S. Luigi Gonzaga, Orbassano, Italy

¹³Medical Oncology Department, Azienda Ospedaliera Universitaria, Pisa, Italy

¹⁴Epidemiology & Clinical Trials Office, General Hospital, Mirano, Italy

¹⁵Oncology Unit, Università Cattolica del Sacro Cuore, Fondazione Policlinico “A. Gemelli”, Rome, Italy

¹⁶Biostatistical Unit, IRCCS Regina Elena National Cancer Institute, Rome, Italy

¹⁷Service de cancérologie médicale, Hôpital Européen Georges Pompidou, René Descartes University, Paris, France

The authors would like to apologise for any inconvenience caused.

Address for correspondence: Orazio Caffo, MD, Medical Oncology Department, Santa Chiara Hospital, Largo Medaglie d'Oro, 38122 Trento, Italy E-mail contact: orazio.caffo@apss.tn.it